Compositions and methods to treat vision disorders
View Patent ↗The present invention provides sterols and uses thereof to treat vision disorders. In one embodiment, composition comprising pharmaceutically effective amount of lanosterol is used to treat and/or prevent vision disorders in a subject. In another embodiment, composition comprising pharmaceutically effective amount of lanosterol is used to treat cataract or blindness/impaired vision in a subject. In yet another embodiment, composition comprising lanosterol is used to dissolve amyloid-like fibrils of crystallin proteins.
1. A method to treat a vision disorder in a subject in need thereof, said method comprises administrating to at least one eye of the subject a composition comprising a pharmaceutically acceptable ophthalmic carrier and a pharmaceutically effective amount of lanosterol, wherein said composition is administered topically, subconjunctivally, retrobulbarly, periocularly, subretinally, suprachoroidally, or intraocularly, wherein said composition is formulated as an ophthalmic solution, an ophthalmic gel, an ophthalmic ointment, an ophthalmic wash, an intraocular infusion solution, a wash for anterior chamber, or preservative for extracted cornea; wherein said lanosterol dissolves crystallin protein aggregate in the at least one eye of said subject; and wherein said vision disorder is selected from the group consisting of cataract, congenital cataracts, cortical opacities, posterior subcapsular cataract, presbyopia nuclear sclerosis, retinal degenerative disorder, Refsum disease, Smith-Lemli-Opitz syndrome, Schnyder crystalline corneal dystrophy, drusen, age-related macular degeneration, and diabetic retinopathy.
2. The method of claim 1 , wherein said subject is having or at risk of developing a vision disorder that affects the normal structure of the lens in the at least one eye.
3. The method of claim 1 , wherein the vision disorder is cataract, and wherein said lanosterol dissolves lens crystallin protein aggregate in the at least one eye of said subject.
4. The method of claim 3 , wherein the lens crystallin protein is selected from α-crystallin, β-crystallin, γ-crystallin, or combinations thereof.
5. The method of claim 1 , wherein said subject is selected from the group consisting of amphibians, reptiles, avians, and mammals.
6. The method of claim 5 , wherein said mammal is selected from the group consisting of rodents, cats, dogs, pigs, horses and humans.
7. The method of claim 1 , wherein the lanosterol is administered in a sufficient amount and duration to dissolve amyloid-like fibrils of crystallin proteins.
8. The method of claim 7 , wherein the method is done in situ, in vitro or in vivo.
9. The method of claim 7 , wherein the crystallin protein is selected from α-crystallin, β-crystallin, γ-crystallin, or combinations thereof.
10. The method of claim 1 , wherein the subject is human.
11. The method of claim 1 , wherein the composition is administered topically.
12. The method of claim 1 , wherein the vision disorder is cataract.
13. The method of claim 1 , wherein the pharmaceutically acceptable carrier is selected from water, a buffer, or a solution of sodium chloride.
14. The method of claim 1 , wherein the pharmaceutically acceptable carrier is a gel.
15. The method of claim 1 , wherein the pharmaceutically acceptable carrier is an ointment.
16. The method of claim 1 , wherein the pharmaceutically acceptable carrier is a cyclodextrin.